- Home
- LXEO vs NKTX Comparison
LXEO vs NKTX Comparison
Compare LXEO & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- NKTX
- Stock Information
- Founded
- LXEO 2017
- NKTX 2015
- Country
- LXEO United States
- NKTX United States
- Employees
- LXEO 72
- NKTX N/A
- Industry
- LXEO
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- NKTX Health Care
- Exchange
- LXEO Nasdaq
- NKTX Nasdaq
- Market Cap
- LXEO 154.0M
- NKTX 131.3M
- IPO Year
- LXEO 2023
- NKTX 2020
- Fundamental
- Price
- LXEO $2.69
- NKTX $1.93
- Analyst Decision
- LXEO Strong Buy
- NKTX Strong Buy
- Analyst Count
- LXEO 5
- NKTX 6
- Target Price
- LXEO $22.20
- NKTX $15.00
- AVG Volume (30 Days)
- LXEO 892.8K
- NKTX 657.1K
- Earning Date
- LXEO 05-20-2025
- NKTX 05-20-2025
- Dividend Yield
- LXEO N/A
- NKTX N/A
- EPS Growth
- LXEO N/A
- NKTX N/A
- EPS
- LXEO N/A
- NKTX N/A
- Revenue
- LXEO N/A
- NKTX N/A
- Revenue This Year
- LXEO N/A
- NKTX N/A
- Revenue Next Year
- LXEO N/A
- NKTX N/A
- P/E Ratio
- LXEO N/A
- NKTX N/A
- Revenue Growth
- LXEO N/A
- NKTX N/A
- 52 Week Low
- LXEO $1.45
- NKTX $1.31
- 52 Week High
- LXEO $19.50
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- LXEO 41.96
- NKTX 51.05
- Support Level
- LXEO $2.77
- NKTX $1.81
- Resistance Level
- LXEO $3.35
- NKTX $2.16
- Average True Range (ATR)
- LXEO 0.62
- NKTX 0.16
- MACD
- LXEO -0.09
- NKTX -0.02
- Stochastic Oscillator
- LXEO 0.69
- NKTX 25.53
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.